81 related articles for article (PubMed ID: 15475475)
1. High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs.
Giuliano KA; Chen YT; Taylor DL
J Biomol Screen; 2004 Oct; 9(7):557-68. PubMed ID: 15475475
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Taxol-induced cell death are concentration dependent.
Torres K; Horwitz SB
Cancer Res; 1998 Aug; 58(16):3620-6. PubMed ID: 9721870
[TBL] [Abstract][Full Text] [Related]
3. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
Giannakakou P; Robey R; Fojo T; Blagosklonny MV
Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
[TBL] [Abstract][Full Text] [Related]
4. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.
Jaks V; Jõers A; Kristjuhan A; Maimets T
Oncogene; 2001 Mar; 20(10):1212-9. PubMed ID: 11313865
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
6. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.
Oldham EA; Li C; Ke S; Wallace S; Huang P
Int J Oncol; 2000 Jan; 16(1):125-32. PubMed ID: 10601557
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin and Zeocin can increase p53 levels during all cell cycle stages.
Houser S; Koshlatyi S; Lu T; Gopen T; Bargonetti J
Biochem Biophys Res Commun; 2001 Dec; 289(5):998-1009. PubMed ID: 11741290
[TBL] [Abstract][Full Text] [Related]
8. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Ling YH; Zou Y; Perez-Soler R
Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Exp Cell Res; 1998 May; 241(1):96-101. PubMed ID: 9633517
[TBL] [Abstract][Full Text] [Related]
11. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
12. Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage.
Nehmé A; Lee BL; Baskaran R; Zhang Q; Lin X; Christen RD
Br J Cancer; 2000 Nov; 83(10):1360-6. PubMed ID: 11044362
[TBL] [Abstract][Full Text] [Related]
13. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
14. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC
Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
Chun E; Lee KY
Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of isoobtusilactone A from Cinnamomum kotoense: involvement of apoptosis, cell-cycle dysregulation, mitochondria regulation, and reactive oxygen species.
Chen CY; Chen CH; Lo YC; Wu BN; Wang HM; Lo WL; Yen CM; Lin RJ
J Nat Prod; 2008 Jun; 71(6):933-40. PubMed ID: 18489163
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
18. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo.
Hsu YL; Cho CY; Kuo PL; Huang YT; Lin CC
J Pharmacol Exp Ther; 2006 Aug; 318(2):484-94. PubMed ID: 16632641
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis.
Demidenko ZN; Kalurupalle S; Hanko C; Lim CU; Broude E; Blagosklonny MV
Oncogene; 2008 Jul; 27(32):4402-10. PubMed ID: 18469851
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
